Drug intelligence / Profile preview

MicroMTx003

Development stage: Preclinical
Lead developer: MicroCrispr
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

MicroMTx003 is an mRNA-based therapeutic candidate being developed by MicroCrispr for the treatment of ischemic heart disease, specifically coronary artery disease. Currently in the preclinical stage, the drug utilizes mRNA technology to potentially address the underlying pathology of myocardial ischemia. While specific target proteins or encoded sequences have not been publicly disclosed, the therapeutic approach aims to leverage MicroCrispr's platform to deliver genetic instructions directly to cardiac tissues to promote repair or improve vascularization.

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on MicroMTx003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroMTx003.

Explore the full profile